Arcellx (ACLX) Enterprise Value (2021 - 2025)
Arcellx's (ACLX) quarterly Enterprise Value came in at -$450.3 million in Q4 2025, up 23.33% year-on-year from -$365.1 million in Q4 2024, and up 2.39% quarter-over-quarter from -$461.4 million in Q3 2025.
Arcellx (ACLX) Enterprise Value (2021 - 2025) Analysis & Trends
Arcellx's Enterprise Value history runs 5 years deep, the most recent figure standing at -$450.3 million for Q4 2025.
- On a quarterly basis, Enterprise Value rose 23.33% year-over-year to -$450.3 million in Q4 2025; TTM through Dec 2025 was -$450.3 million, a 23.33% increase from a year earlier, with the FY2025 full-year figure at -$450.3 million, up 23.33% from the prior year.
- Enterprise Value grew to -$450.3 million in Q4 2025 per ACLX's latest filing, from -$461.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$62.3 million in Q2 2025 and bottomed at -$702.0 million in Q4 2023.
- The 5-year median for Enterprise Value is -$245.9 million (2022), against an average of -$300.1 million.
- Across the five-year window, Enterprise Value tumbled 993.84% in 2023 and jumped 80.21% in 2024, its largest moves.
- Year by year, Enterprise Value stood at -$104.6 million in 2021, then soared by 38.65% to -$64.2 million in 2022, then tumbled by 993.84% to -$702.0 million in 2023, then increased by 16.33% to -$587.4 million in 2024, then gained by 23.33% to -$450.3 million in 2025.
- Per Business Quant, the three latest ACLX Enterprise Value figures stand at -$450.3 million (Q4 2025), -$461.4 million (Q3 2025), and -$62.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -450.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -450.33 Mn |
| Sep 30, 2025 | -461.38 Mn |
| Jun 30, 2025 | -62.34 Mn |
| Mar 31, 2025 | -543.27 Mn |
| Dec 31, 2024 | -587.38 Mn |
| Sep 30, 2024 | -162.05 Mn |
| Jun 30, 2024 | -100.23 Mn |
| Mar 31, 2024 | -154.78 Mn |
| Dec 31, 2023 | -702.02 Mn |
| Sep 30, 2023 | -439.72 Mn |
| Jun 30, 2023 | -506.48 Mn |
| Mar 31, 2023 | -533.59 Mn |
| Dec 31, 2022 | -64.18 Mn |
| Sep 30, 2022 | -280.78 Mn |
| Jun 30, 2022 | -306.99 Mn |
| Mar 31, 2022 | -210.93 Mn |
| Dec 31, 2021 | -104.62 Mn |
| Sep 30, 2021 | -70.03 Mn |
| Jun 30, 2021 | -143.79 Mn |
| Mar 31, 2021 | -117.65 Mn |